Anti-CD20 Antibody Therapy for B-Cell Lymphomas | NEJM
Frontiers | Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better? | Current Oncology Reports
Protéine CD20 pleine longueur exprimée HEK293 avec Nanodisc / DDM / VLP - ACROBiosystems
Brain Sciences | Free Full-Text | Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies | Bentham Science
Learning multiple sclerosis immunopathogenesis from anti-CD20 therapy | PNAS
The future of anti-CD 20 monoclonal antibodies : are we making progress ? | Semantic Scholar
CD20 Antigen Things to Know | Massive Bio
Mechanisms of action of anti-CD20 monoclonal antibodies. Abbreviation:... | Download Scientific Diagram
CD20 antigen structure and organization into membrane bilayers. (A) The... | Download Scientific Diagram
The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy | Haematologica
An Overview of CD20 Monoclonal Antibodies Drugs- CUSABIO
CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure | Haematologica
Frontiers | Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
iLite® CD20 (+) Target
Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis | CNS Drugs
The reduction of B cells by anti-CD20 antibodies includes 6 mechanisms.... | Download Scientific Diagram
CD-20 - Micromega
Frontiers | Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
Development of Anti-CD20 Antigen-Targeting Therapies for B-cell Lymphoproliferative Malignancies - The State of the Art | Bentham Science
Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises | Immunotherapy
CD20 — Wikipédia
Unraveling the T–B tangle in anti-CD20 multiple sclerosis therapy | PNAS
